Ewg Elevate Inc. Altimmune, Inc. Transaction History

Ewg Elevate Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	SELL	$8.22 - $13.81 $41,100 - $69,050	-5,000 Reduced 33.33%	10,000 $101,000
Q4 2023 Jan 08, 2024	BUY	$2.14 - $11.62 $10,700 - $58,099	5,000 Added 50.0%	15,000 $168,000
Q3 2023 Oct 10, 2023	SELL	$2.4 - $3.45 $38,400 - $55,200	-16,000 Reduced 61.54%	10,000 $26,000
Q2 2023 Jul 12, 2023	BUY	$3.45 - $5.97 $89,700 - $155,220	26,000 New	26,000 $91,000

186

39.4M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $329M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Ewg Elevate Inc., based on Form 13F filings with the SEC.

Stay updated on Ewg Elevate Inc. with notifications on news.